Luveltamab tazevibulin
Phase 1/2Terminated 2 views this week 0 watching💤 Quiet
Interest: 14/100
14
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia (AML)
Conditions
Acute Myeloid Leukemia (AML)
Trial Timeline
Dec 4, 2024 → Jun 1, 2025
NCT ID
NCT06679582About Luveltamab tazevibulin
Luveltamab tazevibulin is a phase 1/2 stage product being developed by Sutro Biopharma for Acute Myeloid Leukemia (AML). The current trial status is terminated. This product is registered under clinical trial identifier NCT06679582. Target conditions include Acute Myeloid Leukemia (AML).
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia (AML) were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
9
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06679582 | Phase 1/2 | Terminated |
| NCT06555263 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Acute Myeloid Leukemia (AML)